Sign in to continue:

Thursday, April 30th, 2026

南京健友生化制药拟申请2026年最高95亿元综合授信及为子公司提供担保公告

健友股份重大授信及担保公告:对投资者影响深度解析

健友股份公告:2026年综合授信及重大担保计划,潜在影响与细节解读

关键要点总结

  • 健友股份(603707)拟申请2026年综合授信额度不超过人民币95亿元,其中为全资子公司担保额度不超过85亿元。
  • 被担保人包括南京健智自明医药贸易有限公司和香港健友实业有限公司,均为公司全资子公司。
  • 授信品种覆盖短期流动资金贷款、中长期借款、银行承兑汇票、保函、信用证、抵押贷款、外汇衍生产品等。
  • 公司拟以自有房地产向中国进出口银行江苏省分行贷款不超过7亿元作最高额抵押担保。
  • 截至2025年12月31日,公司无逾期对外担保,内部担保余额为4.35亿元,占净资产6.3%。对外担保余额为零。
  • 本次综合授信及担保事项尚需股东大会批准。

对投资者及股东的潜在影响

  • 融资能力提升:本次授信将提升公司及子公司融资能力,为2026年度经营目标提供资金保障,有助于支持业务扩张与运营。
  • 资金成本降低:通过综合授信,公司可降低融资成本,提高资本运营效率,有利于利润增长。
  • 担保风险可控:被担保方均为全资子公司,董事会与审计委员会认为风险可控且不会损害公司及投资者利益。
  • 资产抵押与流动风险:公司将以自有房地产提供最高额抵押担保,若子公司经营出现风险,可能影响公司资产安全。
  • 财务状况透明:公告中详细披露子公司资产、负债、利润数据,健智自明盈利,香港健友亏损,需投资者注意其经营状况。
  • 重大事项需股东会决策:所有授信及担保事项尚须股东大会表决,未来存在不确定性。

细节解读:授信与担保结构

  • 授信额度可循环使用,实际融资金额以公司运营需求为准。
  • 健友股份为健智自明担保额度不超过55亿元,为香港健友担保额度不超过30亿元。
  • 公司与进出口银行的授信中,拟以自有房地产作抵押,具体担保范围与责任以实际合同为准。
  • 公司及子公司审计数据已由公证天业会计师事务所审计。
  • 董事会及审计委员会均已审议通过,认为对子公司担保有充分控制力,不存在损害投资者利益情况。

财务数据披露(截至2025年12月31日)

公司名称 资产总额(万元) 净资产(万元) 净利润(万元) 负债总额(万元) 流动负债总额(万元) 营业收入(万元)
健智自明 194,046.55 60,300.35 1,813.45 133,746.20 132,892.60 152,522.44
香港健友 279,186.05 24,772.77 -12,087.91 254,413.28 254,413.28 151,667.81

健智自明实现盈利,香港健友出现亏损,投资者需关注香港健友的经营风险。

董事会与审计委员会意见

  • 董事会一致认为授信及担保事项符合监管要求,风险可控。
  • 审计委员会认为公司对被担保子公司有充分控制力,资金使用可监控,担保事项不会损害投资者利益。

累计担保情况

  • 内部担保余额为4.35亿元,占净资产6.3%,无逾期担保。
  • 对外担保总额为零。

投资者关注事项及潜在股价影响

  • 授信规模巨大,将直接影响公司财务结构和资金流动性,若股东会通过,可能提升公司扩张能力和市场信心,对股价形成正面推动。
  • 香港健友亏损需要关注,如未来经营改善将利好公司业绩,如亏损加剧可能拖累集团整体利润。
  • 重大资金安排若有变动或未获股东会批准,可能对公司融资能力、经营计划产生影响。

结语

健友股份本次授信及担保规模创下公司历史新高,若顺利获批,将提升公司及子公司资金实力,有助于业务扩张与市场竞争力。但投资者需重点关注香港健友的经营状况及授信审批进度,相关事项均属重大敏感信息,可能对公司股价产生实质性影响。

免责声明

本新闻稿仅用于信息披露,不构成投资建议。投资者应结合自身情况及公司后续公告,谨慎决策。公司未来经营及授信担保事项存在不确定性,股东会审批结果及子公司经营变化均可能影响公司业绩与股价。


English Version
Key Analysis: Nanjing Jianyou Biochemical Pharmaceutical Co. Large-scale Credit & Guarantee Plan for 2026

Jianyou Shares: 2026 Comprehensive Credit and Major Guarantee Plan, Investor Impact & Details

Key Points

  • Jianyou Shares (603707) plans to apply for a comprehensive credit line up to RMB 9.5 billion for 2026, including guarantee for subsidiaries up to RMB 8.5 billion.
  • Guarantee recipients are Nanjing Jianzhi Zhiming Pharmaceutical Trading Co. and Hong Kong Jianyou Industrial Co., both wholly-owned subsidiaries.
  • Credit types include short-term loans, medium/long-term loans, bank acceptance bills, guarantees, letters of credit, mortgage loans, FX derivatives, FX hedging, etc.
  • The company plans to use its own real estate as maximum mortgage guarantee for up to RMB 700 million loan with China Exim Bank Jiangsu Branch.
  • As of Dec 31, 2025, the company had no overdue external guarantees; internal guarantee balance is RMB 435 million, 6.3% of net assets. External guarantee balance is zero.
  • The plan must be approved by the shareholders’ meeting.

Potential Impact for Investors & Shareholders

  • Enhanced Financing Ability: The credit plan will improve the company and subsidiaries’ financing capabilities, supporting 2026 business targets and expansion.
  • Lower Funding Costs: Comprehensive credit can reduce financing costs and improve capital efficiency, potentially boosting profits.
  • Controllable Guarantee Risk: Board and Audit Committee believe risks are controllable as recipients are wholly-owned subsidiaries.
  • Asset Mortgage & Liquidity Risk: Use of real estate as collateral means company assets are exposed if subsidiary operations face risks.
  • Transparent Financials: The announcement discloses subsidiary asset, liability, and profit data. Jianzhi Zhiming is profitable; Hong Kong Jianyou is loss-making—investors should monitor subsidiary performance closely.
  • Shareholder Approval Required: All credit and guarantee plans are subject to shareholder vote, future uncertainties exist.

Credit & Guarantee Structure Details

  • Credit is revolving; actual financing will be determined by operational needs.
  • Guarantee for Jianzhi Zhiming up to RMB 5.5 billion, Hong Kong Jianyou up to RMB 3 billion.
  • Mortgage guarantee for Exim Bank loan uses company real estate; specific terms per actual contract.
  • Financials audited by Gongzheng Tianye CPA.
  • Board and Audit Committee have reviewed and approved, believe control and monitoring are sufficient and no investor harm.

Financial Data (as of Dec 31, 2025)

Company Name Total Assets (mn RMB) Net Assets (mn RMB) Net Profit (mn RMB) Total Liabilities (mn RMB) Current Liabilities (mn RMB) Revenue (mn RMB)
Jianzhi Zhiming 1,940.47 603.00 18.13 1,337.46 1,328.93 1,525.22
Hong Kong Jianyou 2,791.86 247.73 -120.88 2,544.13 2,544.13 1,516.68

Jianzhi Zhiming is profitable; Hong Kong Jianyou is loss-making. Investors should monitor Hong Kong Jianyou’s performance.

Board & Audit Committee Opinions

  • Board unanimously agrees the plan fits regulatory requirements and is controllable.
  • Audit Committee believes company has sufficient control, monitoring, and guarantee does not harm investor interests.

Cumulative Guarantee Situation

  • Internal guarantee balance RMB 435 million, 6.3% of net assets, no overdue guarantees.
  • External guarantee total is zero.

Investor Concerns & Potential Share Price Impact

  • The scale of the credit plan could significantly affect financial structure and cash flow. If approved, it may boost expansion ability and market confidence, potentially pushing share price up.
  • Hong Kong Jianyou’s losses need close watch; if performance improves, it will be positive for group profits, but continued losses may drag down overall results.
  • Major funding plans remain subject to shareholder approval; any change or rejection could impact financing and business plans.

Conclusion

Jianyou Shares’ credit and guarantee plan marks a record scale for the company. If approved, it will strengthen financial resources and competitiveness. Investors should closely monitor Hong Kong Jianyou’s performance and shareholder meeting outcome. All matters are highly sensitive and may materially impact share price.

Disclaimer

This news release is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and future announcements before making decisions. There is uncertainty in future operations and credit guarantee plans, and shareholder approval and subsidiary performance may affect company results and share price.


View 健友股份 Historical chart here



国投资本股份有限公司2026年股份回购实施结果及股份变动公告

国投资本股份有限公司公布股份回购实施结果及股份变动公告 公告要点 回购方案首次披露日:2025年4月10日 ...

新点软件首次以集中竞价回购股份进展公告(2026年4月)

国泰新点软件首次回购股份公告详解 | Investor News 国泰新点软件以集中竞价方式首次回购公司股份,彰显对...

四川路桥2025年度利润分配方案公告:每股派息0.46元,分红总额超42亿元

四川路桥公布2025年度利润分配方案,拟派发高额现金红利 四川路桥建设集团股份有限公司(600039)于2026年4月...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today